Bangalore, India — (PRESS RELEASE JET) — 09/27/2017 — Viral Conjunctivitis – Pipeline Review, H2 2017, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.
Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.
Viral Conjunctivitis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively.
Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
– The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 38 pages “Viral Conjunctivitis – Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Viral Conjunctivitis – Overview, Viral Conjunctivitis – Therapeutics Development, Pipeline Overview, Viral Conjunctivitis – Therapeutics Assessment, Viral Conjunctivitis – Companies Involved in Therapeutics Development, Viral Conjunctivitis – Drug Profiles, Product Description, Viral Conjunctivitis – Dormant Projects, Appendix. This report Covered Companies – Adenovir Pharma AB, NanoViricides Inc, Panoptes Pharma GesmbH, Shire Plc.
For more information Visit at: http://www.drugpipeline.net/global-markets-direct/viral-conjunctivitis-pipeline-review-h2-2017
Find all Pharma and Healthcare Reports at – http://www.drugpipeline.net/catalog/pharma-healthcare
Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H2 2017 – Visit at – http://www.drugpipeline.net/global-markets-direct/influenza-virus-h3n2-subtype-infections-pipeline-review-h2-2017
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2017 – Visit at – http://www.drugpipeline.net/global-markets-direct/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-1
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.
Powered by WPeMatico